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Abstract
Background: Yttrium-90 (90Y) radioembolization involves the intra-arterial delivery of
radioactive microspheres to treat hepatic malignancies. Though this therapy involves
careful pre-treatment planning and imaging, little is known about the precise
location of the microspheres once they are administered. Recently, there has been
growing interest post-radioembolization imaging using positron-emission
tomography (PET) for quantitative dosimetry and identifying lesions that may benefit
from additional salvage therapy. In this study, we aim to measure the inter-center
variability of 90Y PET measurements as measured on PET/MRI in preparation for a
multi-institutional prospective phase I/II clinical trial.
Eight institutions participated in this study and followed a standardized phantom
filling and imaging protocol. The NEMA NU2-2012 body phantom was filled with
3 GBq of 90Y chloride solution. The phantom was imaged for 30 min in listmode on
a Siemens Biograph mMR non-TOF PET/MRI scanner at five time points across
10 days (0.3–3.0 GBq). Raw PET data were sent to a central site for image
reconstruction and data analysis. Images were reconstructed with optimal
parameters determined from a previous study. Volumes of interest (VOIs) matching
the known sphere diameters were drawn on the vendor-provided attenuation map
and propagated to the PET images. Recovery coefficients (RCs) and coefficient of
variation of the RCs (COV) were calculated from these VOIs for each sphere size and
activity level.
Results: Mean RCs ranged from 14.5 to 75.4%, with the lowest mean RC coming
from the smallest sphere (10 mm) on the last day of imaging (0.16 MBq/ml) and the
highest mean RC coming from the largest sphere (37 mm) on the first day of
imaging (2.16 MBq/ml). The smaller spheres tended to exhibit higher COVs. In
contrast, the larger spheres tended to exhibit lower COVs. COVs from the 37 mm
sphere were < 25.3% in all scans. For scans with ≥ 0.60 MBq/ml, COVs were ≤ 25% in
spheres ≥ 22 mm. However, for all other spheres sizes and activity levels, COVs were
usually > 25%.
Conclusions: Post-radioembolization dosimetry of lesions or other VOIs ≥ 22 mm in
diameter can be consistently obtained (< 25% variability) at a multi-institutional level
using PET/MRI for any clinically significant activity for 90Y radioembolization.
Keywords: Yttrium-90, PET, PET/MRI, Radioembolization
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Background
Yttrium-90 (90Y) radioembolization involves the intra-arterial delivery of radioactive
microspheres to primary or metastatic disease in the liver. 90Y decays primarily
with β− emission (mean 0.937 MeV, 64.2 h half-life, 2.5 mm mean soft tissue penetration, 11 mm max tissue penetration) [1], allowing for high amount of radiation
dose within a well-confined region. The current commercially available microspheres, TheraSpheres (glass microspheres; BTG, London, UK) and SIR-Spheres
(resin microspheres; Sirtex Medical, Sydney, Australia), were first approved in the
USA by the Food and Drug Administration in 1999 and 2002 and received the
European CE mark in 2005 and 2002, respectively [2, 3]. Since then, 90Y microsphere radioembolization has continued to grow as a third-line therapy for patients
with some clinical trials into using this technology as a first-line therapy concurrent with FOLFOX-based chemotherapy [4]. While the use of 90Y microspheres to
treat cancer in the liver has been utilized for over 50 years [5], the treatment planning protocol from pre-treatment imaging to prescription activity calculation is not
well optimized. Standard protocol does not allow for assessing the actual distribution of the microspheres or for predicting the effectiveness of treatment or possible
toxicity events without waiting for follow-up imaging studies at least 30 days after
treatment [6]. Patients who undergo 90Y radioembolization typically have poor
prognoses and earlier assessment of therapy immediately after injection could guide
optimization of therapy.
Recently, there has been an interest in performing post-radioembolization imaging
and dosimetry to assess the microsphere distribution and predict clinical outcomes.
Early work involved Bremsstrahlung SPECT, utilizing the high Bremsstrahlung flux
from the β− emission of 90Y [7–9]. However, these images suffer from poor spatial
resolution, making it difficult to identify small areas of uptake and the heterogeneous
distribution of the microspheres [10, 11] as well as perform quantitative evaluation.
Early case studies found that the small positron yield (0.0032%) of 90Y was sufficient
for imaging the microsphere distribution by PET [12–14]. Since then, several singlecenter studies have reported the ability to predict clinical outcomes using dosimetry
derived from 90Y PET images following radioembolization in both primary liver cancer
[15] and metastatic colorectal cancer [16–18].
Multi-center clinical studies with quantitative end points, typically involves imaging a
standard phantom to test quantitative accuracy and inter-center variability. Fahey et al.
evaluated inter-center reproducibility and variability in a multi-center study involving
fluorine-18 (18F) on PET/CT [19]. Another similar study was performed by Willowson
et al. in the multi-center QUEST phantom study for measuring inter-site variability of
90
Y on PET/CT [20].
The purpose of this study is to measure both the inter- and intra-center variability of quantitatively measuring 90Y on PET/MR in preparation for a multi-center
phase I/II clinical trial (NCT02611661). Our study mirrors the work that was performed by Willowson et al. in the QUEST study but, due to the difference in scanner designs and electronics, focuses instead on PET/MRI scanners. Furthermore,
this study uses the same PET/MRI system model and identical reconstruction
parameters across all centers, rather than allowing centers to reconstruction their
own data with their own parameters. This was to test the true performance of the
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scanner with 90Y without extra uncertainty introduced by varying choices in reconstruction parameters.

Methods
A total of eight institutions across four countries participated in this phantom study. All
sites followed a strict protocol for both filling and imaging the phantom. Three NEMA
NU2-2012 image quality (IQ) body phantoms (PTW Freiburg GmbH, Freiburg, Germany)
with vendor-provided foam cradles and positioning devices were shared between the eight
institutions.
Phantom preparation

Before filling the phantom with activity, the volume of the background compartment
was measured by its water weight.
3.6 GBq in 1.4 mL of 90Y chloride solution (PerkinElmer, Waltham, MA) was shipped
to each institution. The supplier’s calibrated activity listed on the shipping document
was used as the “ground truth” for the activity within the vial. Each site recorded the
amount of activity reported by their department’s dose calibrator for comparison
against the reported amount on the shipping label. The manufacturer and model of
each site’s dose calibrator is listed in Table 1.
The entire contents of the vial were completely emptied into 1300 mL of water with
100 mg of either DTPA or EDTA added to prevent binding of 90Y chloride to the walls
of the phantom. Activity was drawn from this solution to fill the six spheres (diameters
37, 28, 22, 17, 13, and 10 mm). Once all spheres were filled, the remaining solution was
emptied into the background compartment of the NEMA IQ phantom, and the
remaining volume of the background compartment was filled with water. This resulted
in an approximately 8:1 sphere-to-background activity concentration ratio. The center
lung insert for the phantom was a solid structure made of polyethylene material. The
total recorded activity in the phantom was the total activity listed on the shipping
document minus any residual activity in the vial and syringe.
Image acquisition and reconstruction

The phantom was imaged at five time points (day 0, day 3, day 5, day 7, and day
10) at each institution on Siemens Biograph mMR non-time-of-flight (non-TOF)
Table 1 Dose calibrator and settings used at each site to measure
that reported on shipping label

90

Y activity and verify against

Site number Dose calibrator manufacturer Model

Setting for 90Y

1

Capintec

CRC-12

Channel 53 × 10

2

Capintec

CRC-55 T PET

Channel 010

3

Capintec

CRC-15R

Channel 48 × 10

4

Capintec

CRC-15R

Channel 56 × 10

5

Capintec

55 t W

Channel 48 × 10

6

Veenstra Instruments

VIK 2025051

Factor 902, scale 100

7

MED

ISOMED 2010 Factor 2.3 (geometry: 3 ml syringe/1.4 ml solution)

8

Capintec

CRC-15R

Channel 48 × 10
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PET/MRI scanners, representing a range of total activities from 0.3 to 3.0 GBq.
These values correspond to the full range of activities administered to patients
treated with resin microspheres. The phantom was positioned in a foam cradle
with an accompanying positioning device, as described by Ziegler et al. [21], to
center the phantom in the field of view (FOV) and allow for reproducible placement of the phantom between scans and institutions. The phantom was imaged for
30 min in listmode acquisition in a single station. Due to the longer axial FOV of
the Biograph mMR (25.6 cm), we are able to reduce the number of stations
compared to other scanners with a shorter FOV (e.g., 15–16 cm), which typically
require a minimum of two stations [20]. For post-radioembolization patients at our
clinic (WUSM), we acquire PET data in a single station. At one of the sites, three
back-to-back PET acquisitions (same phantom filling) were performed to evaluate
intra-center variability. Another site (Washington University, St. Louis, MO) repeated the phantom filling with 54.4 MBq fluorine-18 (18F) and imaged at a single
time point (15 min listmode acquisition) for comparison to a high statistic dataset.
This 18F dataset was also reconstructed into ten smaller datasets, consisting of 3 s
each of listmode data, to contain a similar amount of trues statistics to that seen
in the 90Y PET data. Those same ten data sets were reconstructed with additional
randoms added to the sinograms to obtain a similar randoms fraction as that observed in the 90Y PET data. A detailed description of these methods are described
in [22]. This was to compare measurements from 18F data containing a similar
amount of trues count statistics as that exhibited in 90Y PET data on the highest
activity day of imaging.
All raw PET data were sent via a secure data server (ABX-CRO Advanced Pharmaceutical
Services, Dresden, Germany) to a central site (Washington University, St. Louis,
MO) for reconstruction and analysis by a single investigator (N.M.). All PET
reconstructions were performed using e7tools, the offline research reconstruction
software provided by Siemens, with a vendor-provided, CT-derived attenuation
map of the NEMA 2007/IEC 2008 Body phantom for attenuation correction, as
described by Ziegler et al. [21] The attenuation map was manually inspected and registered for each PET data set since they were not measured directly from the PET/MRI
scanner. Images were reconstructed with 3D ordinary Poisson ordered subset expectation
maximization (OP-OSEM), with the following parameters determined from a previous
phantom study: 3 iterations, 21 subsets, 5 mm full-width-half-maximum Gaussian postreconstruction filter, point spread function (PSF) compensation, and using absolute scatter correction with 4.17 × 4.17 × 2.03 mm3 voxels [23].

Image post-processing and analysis

All image post-processing, including drawing volumes of interest (VOIs) and extracting
statistics from those VOIs, was performed in MIM v6.6.7 (MIM Software, Cleveland,
OH). VOIs were drawn on the attenuation map of the phantom (see Fig. 1). The VOIs on
the spheres were drawn as spherical VOIs with a diameter matching the known sphere
diameter. The VOIs with their corresponding purpose for quantitative assessment,
according to NEMA NU 2-2007 guidelines, are summarized in Table 2. Each PET image
was fused to the corresponding attenuation map for transfer of VOIs.
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Fig. 1 Attenuation map of NEMA 2007/IEC 2008 body phantom with VOIs drawn around each of the six
fillable spheres, 72 VOIs drawn in the background compartment, and a 28-mm diameter VOI drawn in the
cold insert (center, yellow)

The recovery coefficients (RCs) for each of the fillable sphere and respective background VOIs were calculated to assess accuracy of measurements, especially in regards
to partial volume effects (PVE):
RC ð%Þ ¼

Am
 100
At

ð1Þ

where Am is the measured mean activity concentration and At is the true activity concentration. The coefficient of variation (COV) of RCs for each hot sphere VOI and day
of imaging (8 VOI measurements per COV) was used to quantify both inter- and intracenter variability:
COVi;n ð%Þ ¼

σ i;n
 100
μi;n

ð2Þ

where σi, n is the standard deviation and μi,
(i) and day of imaging (n).

n

is the mean of RCs for a given sphere size

Table 2 Quantities for volume of interest (VOI) analysis
VOI and size

Measured quantity

Purpose

Field of view (FOV)

Total activity (GBq)

Accuracy in total injected activity
measurement

Fillable spheres: 37, 28, 22, 17, 13,
10 mm

Recovery coefficient of mean
activity concentration (MBq/ml)

Accuracy in VOI measurements
from partial volume effects

Background spheres: 12 of 37-mm
diameters

Recovery coefficient of mean
activity concentration (MBq/ml)

Accuracy in warm background
VOI measurements

Background spheres: 12 each of 37-, 28-, Standard deviation of mean
22-, 17-, 13-, 10-mm diameters
activity concentration (MBq/ml)

Variability in warm background
measurements (noise)

Insert: 28-mm diameter, 160-mm length Mean activity concentration
(MBq/ml)

Background counts
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Background variability for each sphere size s (BVs) for the highest activity day of imaging (12 measurements/site × 8 sites = 96 total VOIs) was calculated using
BVs ð%Þ ¼

σs
 100
μs

ð3Þ

where σs is the standard deviation of the 96 background concentration measurements
for a given sphere size s, and μs is the average of the 96 background concentration measurements for a given sphere size s.
Activity in the cold insert (Ci) was quantified using
C i ð%Þ ¼

Am;i
 100
At;b

where Am, i is the measured activity concentration in the cold insert, and At,
true background activity concentration.

ð4Þ
b

is the

Results
Activities reported by each site’s dose calibrator were on average 3.62% lower than that
reported on the shipping label (median − 4.95%, range − 6.31–0.61%). Figure 2 shows
transaxial PET images through the center of the spheres from the first day of imaging
for each site.
After visual inspection and manual registration between the attenuation maps and the
PET data, adequate registration was obtained in all data sets. Most data sets required approximately a few centimeters translation in the axial direction to properly align the attenuation map with the PET data. At some sites, the phantom was positioned in a reversed
direction or the center plate containing the spheres was rotated (Fig. 2), in which case a
rotation was required to properly align the attenuation map with the data.

Fig. 2 PET images from first day of imaging (~ 3.0 GBq) for each of the eight sites

Maughan et al. EJNMMI Physics (2018) 5:7
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Figure 3a shows the measured activity versus true activity within the whole FOV
along the identity line, averaged across the eight sites, and Fig. 3b shows the percent
differences in total measured activity and true activity. The total activity measured
within the FOV had a median error of − 0.63% across all activity ranges from all sites
(8 sites × 5 days of imaging = 40 measurements) (mean 4.71%, range − 23.9–65.0%). All
average measurements of total activity were within ± 10% of true activity for activities ≥
0.5 GBq. The lowest activity measurements (~ 0.3 GBq) overestimated the total activity
within the FOV on average by 25.8% (range − 20.8–65.0%).
Figure 3c shows the mean measured versus true activity concentration in the 37 mm
VOI in the warm background compartment of the phantom along the identity line, and
Fig. 3d shows the percent deviation in this background activity concentration. Mean
measured activity concentration had a median error of − 1.68% across all activity ranges
from all sites (12 measurements/site × 5 imaging days × 8 sites = 480 measurements)
(mean − 1.43%, range − 31.3–32.1%).

a

b

Total Activity

3.5

Total Activity
60
40

2.5
difference (%)

measured activity (GBq)

3

2
1.5

20
0
-20

1
-40
0.5
-60
0
1
2
true activity (GBq)

3

Background

0.35

0

d

1
2
true activity (GBq)

3

Background
60

0.3
40
0.25
difference (%)

c

measured activity concentration (MBq/mL)

0

0.2
0.15

20
0
-20

0.1
-40
0.05
-60
0
0

0.1
0.2
0.3
true activity concentration (MBq/mL)

0

0.1
0.2
0.3
true activity concentration (MBq/mL)

Fig. 3 a Total measured activity within the FOV compared to the true activity, averaged across the
eight sites. The dashed line represents the identity (i.e., where measured equals true). b Error in
measured activity within the FOV. Each point represents the mean measured activity across the eight
sites. Error bars represent one standard deviation across the eight sites’ measurements. The shaded
region represents ± 10% error. c Mean activity concentration of the 37 mm VOI within the warm
background compartment of the phantom compared to the true activity concentration, averaged
across the eight sites. The dashed line represents the identity (i.e., where measured equals true). d
Deviation of measured activity concentration within warm background. Each point represents the
mean measured activity concentration of the 37 mm VOI across the eight sites. Error bars represent
one standard deviation across the eight sites’ measurements. The shaded region represents
± 10% error
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Figure 4 shows the noise in the PET imaging volumes, quantified by both the background variability (Eq. 3, Fig. 4a) and the signal intensity in the cold lung insert normalized by the true background activity (Eq. 4, Fig. 4b). The median background
variability ranged from 6.48 to 32.2%, measured from the largest and the smallest
spheres, respectively, across all sphere sizes (total of 576 warm background VOIs), with
a median variability of 16.5% (mean 16.7%). The median cold insert counts (Ci) increased from 33.3 to 75.6% in the lung insert from 0.29 MBq/ml to the lower true activity concentrations of 0.02 MBq/ml. The median cold insert counts percentage across
40 PET imaging volumes was 45.3% of the true warm background activity concentration (mean 48.8%, range 23.9–104%). In comparison, the cold insert counts normalized
to warm background in the 18F phantom image was 26%.
Figure 5 and Table 3 illustrate the RCs and variation of each sphere size averaged
over the different institutions. The inter-center variability of imaging with 90Y,
expressed as the standard deviation on the RC measured at the different sites, is shown
on the graphs as the error bars. A comparative measurement done with the same phantom but with high statistics 18F is indicated as the solid line on the graphs. The median
RC for each hot sphere across all sites and activity concentrations (5 imaging days × 8
sites = 40 measurements per sphere) was 68.7, 52.4, 46.8, 41.8, 27.5, and 22.0% for the
37-, 28-, 22-, 17-, 13-, and 10-mm spheres, respectively. The highest mean RC for any
given activity concentration and sphere size was 75.4%, measured on the 37-mm sphere
at the highest activity (~ 2.16 MBq/ml). In contrast, the lowest mean RC for any given
activity concentration and sphere size was 14.5%, measured from the 10-mm sphere at
the lowest activity level (~ 0.16 MBq/ml). Agreement with 18F measurements was best
for the largest sphere and at the two highest activity levels (1.00 and 2.16 MBq/ml of
90
Y), with deviation of − 1.7 and − 1.5%, respectively. Variability in measurements increased with decreasing sphere size and decreasing activity.
Figure 6a–e and Table 4 illustrate the RC variability obtained from one site (Norwegian
University of Science and Technology, Trondheim, Norway) who acquired three consecutive scans for each imaging day. The median RC for each hot sphere across the three scans
and all activity concentrations (5 imaging days × 3 scans = 15 measurements per sphere)
was 74.8, 56.9, 55.6, 47.2, 44.1, and 24.3% for the 37-, 28-, 22-, 17-, 13-, and 10-mm
spheres, respectively. . At the highest activity level, variability between scans for all hot

b

Background

80

100

Lung Insert

80
% of background

background variability (%)

a 100

60

40

20

60

40

20

0

0
10

20
30
sphere diameter (mm)

40

0
0.1
0.2
0.3
background activity concentration (MBq/mL)

Fig. 4 a Variability in measurements between 12 × 8 background VOIs for each sphere size. b Misplaced
counts in cold lung insert reported as percent of true background activity concentration. Each point
represents the mean. Error bars represent one standard deviation
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100
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Y
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F

20
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0.36 MBq/ml

100
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80
recovery (%)

40

0
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40
20
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Y

18

F
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20
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Y

18

F

0

0
10

e

60

20

0

c

1.00 MBq/ml

100

20
30
sphere diameter (mm)

40

10

20
30
sphere diameter (mm)

40

0.16 MBq/ml

100

recovery (%)

80
60
40
20

90

Y

18

F

0
10

20
30
sphere diameter (mm)

40

Fig. 5 a–e Recovery coefficients as a function of hot sphere size from five different hot sphere activity
concentrations across all sites. Each point represents the mean RC and error bars represent one standard
deviation across the eight sites. The COV for each sphere size and hot sphere activity concentrations are
shown in Table 3. Measurements from one site’s 18F measurements (54.4 MBq) are shown in black

Table 3 Inter-center coefficient of variation (COV) of recovery coefficients (RCs) for each sphere
size and activity concentration
COV (%) (range)
Sphere diameter (mm)

2.16 MBq/ml

1.00 MBq/ml

0.60 MBq/ml

0.36 MBq/ml

0.16 MBq/ml

10

36.2 (14.0–48.6)

86.6 (6.18–99.8)

75.1 (7.79–51.7)

49.5 (9.83–45.1)

64.1 (2.63–26.9)

13

32.2 (23.5–59.8)

55.1 (18.0–68.3)

92.3 (12.5–112)

44.9 (13.6–49.6)

77.5 (3.47–65.5)

17

29.7 (18.9–69.1)

30.4 (30.3–78.0)

36.4 (27.5–75.8)

47.7 (20.5–75.0)

78.8 (14.7–118)

22

22.7 (41.2–84.1)

22.8 (29.6–63.4)

25.0 (32.6–70.0)

23.7 (30.5–56.1)

37.9 (10.4–49.4)

28

24.1 (42.9–88.1)

21.5 (41.7–80.3)

17.8 (38.0–65.3)

26.8 (26.8–69.6)

15.8 (26.8–46.9)

37

18.0 (56.0–95.0)

22.2 (52.0–103)

18.3 (54.9–92.2)

25.3 (46.4–91.4)

21.1 (45.2–81.3)

Values in parentheses represent the range of RCs (min–max)
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recovery (%)
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0

e

60

20

20

c

1.00 MBq/ml

100
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0

0
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40

10

20
30
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40

Fig. 6 a–e Recovery coefficients as a function of hot sphere size from three consecutive scans at a single
site. Each point represents the mean RC, and error bars represent one standard deviation. The COV for each
sphere size and hot sphere activity concentrations are shown in Table 4. f Measurements from raw 18F data
(black line), 18F data with similar 90Y true count statistics (light blue square), and 18F data with similar true
count statistics and randoms fraction to 90Y. Again, each point represents the mean RC and error bars
represent one standard deviation across the ten 3-s 18F datasets

Table 4 Intra-center coefficient of variation (COV) of recovery coefficients (RCs) for each sphere
size and activity concentration
COV (%) (range)
Sphere diameter (mm)

2.32 MBq/ml

1.06 MBq/ml

0.65 MBq/ml

0.38 MBq/ml

0.17 MBq/ml

10

4.49 (29.7–32.3)

40.2 (20.8–40.2)

59.4 (8.71–24.3)

67.6 (14.4–56.6)

108 (4.42–40.9)

13

7.58 (44.1–51.0)

47.1 (22.6–50.2)

39.7 (27.2–63.3)

32.9 (16.6–30.9)

45.3 (29.1–79.6)

17

12.4 (48.8–60.6)

9.79 (57.5–68.1)

13.4 (40.4–53.0)

34.5 (21.6–43.5)

49.6 (15.6–45.7)

22

5.06 (55.6–61.5)

8.35 (50.2–59.2)

18.2 (43.4–62.0)

36.8 (27.8–57.7)

50.8 (14.5–47.1)

28

6.48 (56.2–63.7)

6.69 (49.9–57.0)

4.89 (58.9–64.3)

23.9 (34.9–56.9)

35.0 (27.2–57.4)

37

1.43 (77.0–79.0)

4.79 (70.1–77.1)

7.52 (66.6–77.0)

16.0 (56.6–77.4)

20.0 (53.9–77.7)

Values in parentheses represent the range of RCs (min–max)

Maughan et al. EJNMMI Physics (2018) 5:7

Page 11 of 18

spheres was < 13% (mean 6.24%, median 5.77%, range 1.42–12.4%). All spheres ≥ 17 mm
with ≥ 0.60 MBq/ml had < 20% variability in their RCs. The 37-mm sphere had a variability in measurements ≤ 20% for all activity levels. Again, variability increased with decreasing sphere size and decreasing activity. Table 5 lists the COV and range for these scans for
RC of total activity and background activity concentration and Ci values of the cold lung
insert. Variability tended to increase with decreasing activity for these VOIs as well, with
the exception of total activity, which tended to remain rather stable. Figure 6f shows measurements from the 18F phantom, reconstructed into smaller data sets with both trues
counts statistics and/or randoms fraction typically seen with 90Y PET data from the highest activity imaging day. Total trues for these smaller 18F data sets were 2.07 × 106 and
those reported by one site for 90Y were 1.54 × 106. The randoms fraction for typical 18F
datasets was 31% and that for the simulated high-randoms was 77%. The randoms fraction for 90Y was approximately 75%.

Discussion
Despite the low positron yield from 90Y, PET imaging of this isotope has proven both
feasible and useful in previous literature [11–13, 15–17, 23, 24] and is further demonstrated in this work. The results from this study and that reported by Willowson et al.
in the PET/CT QUEST study [20] also demonstrate the feasibility of performing multiinstitutional clinical studies focused on 90Y PET-based dosimetry.
Even though this multi-institutional phantom study with 90Y PET imaging has been
performed previously on PET/CT [20], there are several key differences between Siemens Biograph PET/CT scanners and Siemens Biograph mMR (PET/MRI) scanners
that motivate the need to perform this study on PET/MRI. First, the Biograph mMR
utilizes avalanche photodiode (APD) detectors instead of typically used photomultiplier
tubes (PMT), to allow for compatibility with the MR magnetic field. However, this
comes at the cost of not having TOF capabilities. Additionally, compared to the
Biograph PET/CT scanners, the mMR exhibits increased sensitivity due to the geometrical arrangement of the detectors: 15.0 kcps/MBq) [25] versus 8.1 kcps/MBq on the
Biograph 40 (non-TOF) PET/CT [26]. As discussed previously, the difference in sensitivities is due to a longer axial FOV and shorter ring diameter on the Biograph mMR
[23]. The tight geometry and wider coincidence timing window in mMR result in
higher random rates, but the smaller block size results in lower singles rate per detector
block in comparison to Siemens PET/CT scanners [23]. All of these factors (i.e., difference in electronics and higher sensitivity from a different geometry), combined with
low annihilation counts and high randoms rates from Bremsstrahlung radiation, make
Table 5 Intra-center coefficient of variation (COV) between three consecutive scans of recovery
coefficients (RCs) of total activity and background activity concentration and of counts in the cold
lung insert (Ci) on each imaging day
COV (%) (range)
VOI

3.0 GBq

1.4 GBq

0.8 GBq

0.5 GBq

0.2 GBq

Total activity

0.80 (96.7–98.2)

0.47 (102–102)

0.78 (106–107)

0.79 (114–115)

0.80 (139–141)

Background

16.8 (46.5–147)

26.9 (33.6–209)

27.9 (32.8–179)

34.6 (32.8–254)

50.4 (30.5–423)

Lung insert

4.51 (31.5–34.5)

5.99 (39.6–44.6)

2.82 (37.4–39.1)

5.05 (39.9–44.5)

10.2 (61.1–74.1)

Numbers in parentheses represent the range of RCs for total activity and background activity concentration and Ci for
the lung insert (min–max)
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the similarity of the convergence properties of OSEM imaging reconstruction different
between Biograph PET/CT and Biograph PET/MRI scanners. This was demonstrated in
our previous phantom study, where we found that the optimal reconstruction parameters, using the same number of subsets, post-reconstruction filter size, and resolution
recovery, were at three iterations on the mMR instead of two iterations for Biograph
PET/CT scanners, as suggested by Willowson et al. [20]. Therefore, it is necessary to
demonstrate the quantitative accuracy and test the variability between scanners on
mMR, especially since this has not been done.
90
Y has high randoms rates (due to a high flux of Bremsstrahlung radiation) and low
trues statistics (due to low annihilation counts); therefore, a careful handling of the
randoms in the reconstruction proves essential in iterative reconstruction algorithms. In previous generations of OSEM, the pre-subtraction of randoms and
scatter results in significant bias [27, 28]. Siemens mMR uses 3D OP-OSEM with
PROMPTS+RANDOMS data acquisition, as done in Biograph mMR and mCT,
there is no pre-subtraction of scatter or randoms estimates, and therefore the
algorithm bias is reduced [29]. However, in situations of very low counts such with
90
Y imaging, the convergence properties of the algorithm may be such that more
iterations are needed at the expense of increased noise. In our phantom evaluation
[23], we limited the noise in the images by stopping after three 3D OP-OSEM iterations (with 21 subsets resulting in 63 updates) and applying a 5 mm Gaussian
post-reconstruction filter. As shown in [23], images reconstructed with more iterations and sharper filter resulted in unacceptably noisy images. The low count statistics and high randoms fraction for 90Y PET imaging are likely the cause of lower
count recovery compared to higher statistics 18F PET imaging. Evidence of this is
shown in Fig. 6f. Optimized image reconstruction algorithms, with extremely low
count statistics and high random counts, have yet to be resolved [20, 23, 30]. This
is an area of future research.
Recovery of the total activity within the whole FOV was consistent among sites, with
most measurements within ± 10% of the true values, especially above 0.5 GBq. These
values are consistent with those reported by Willowson et al. in the PET/CT QUEST
study for 19 Siemens Biograph TOF PET/CT scanners [20], though our reported standard deviation on the Biograph mMR at 0.5 GBq was slightly higher, likely due to a
smaller number of sites. Our total activity results were closer in agreement with the
expected activity than those reported for Siemens Biograph non-TOF PET/CT scanners
in the same QUEST study, where mean error in the FOV at 0.5 GBq was approximately
+ 20% and standard deviation in this error was approximately ± 60% [20]. Our study
performed an extra scan at a lower activity level (0.3 GBq) that was not performed in
the PET/CT QUEST study. The extra scan at a lower activity level represents the subset
of patients who are administered the lowest activity available for resin microsphere
treatment. Total activity measurements in this range were, on average, overestimated
by > 20%, with a standard deviation reaching beyond ± 20%. This trend in overestimation of total activity with decreasing activity has been reported in previous studies
using both TOF and non-TOF Siemens Biograph PET/CT scanners [20, 24]. A possible
explanation could be extremely low count statistics resulting in higher noise, uncertainty in scatter correction, or artificial peaks in the data resulting in measured activity
higher than the true activity. This effect may be less prominent in TOF reconstructions,
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since it is known that TOF reduces noise by reducing noise propagation in both forward- and back-projections at each iteration [31].
Activity measurements in the warm background compartment of the phantom
were excellent, with the mean error consistently < 10%. These values are consistent
with those reported in the QUEST study for both the Siemens Biograph TOF (> 1
iteration, no post-reconstruction filter reconstructions only) and non-TOF PET/CT
(PROMPTS+RANDOMS reconstructions only) scanners [20]. The standard deviations in our warm background measurements were also comparable to those reported in the QUEST PET/CT study. It is important to note that the background
compartment of the phantom was intended to simulate the non-zero uptake of
normal liver parenchyma, as is commonly seen in clinical studies [15, 16]. Even
though liver tumors tend to take up higher concentrations of the 90Y microspheres,
which is the goal of radioembolization, the normal liver parenchyma often takes up
some of the microspheres as well, albeit usually at a lower concentration. Thus, it
was imperative to include warm background activity in the large compartment of
the phantom in an attempt to simulate the clinical setting. In our experience, the
ratio of tumor:normal liver (“background”) activity concentrations varies from patient to patient. Future work includes investigating the effects of tumor:background
activity concentrations on image quality.
Noise in the PET imaging volumes was quantified by both the background variability
on the high activity day of imaging (~ 0.29 MBq/ml) (Eq. 3) and the scatter/background
counts in the cold (no activity) lung insert of the phantom (Eq. 4). Background variability on the Biograph mMR was significantly lower than that reported for both the TOF
and non-TOF Biograph PET/CT scanners in the QUEST study (16.7% mean versus ~
30, 50, and 38% means for TOF and Gaussian post-reconstruction filter, TOF and no
post-reconstruction filter, and non-TOF reconstructions, respectively) [20]. However,
scatter counts in the lung insert from the mMR (49.0% mean) were higher than those
from Biograph TOF PET/CT scanners (~ 30% mean) and non-TOF PET/CT scanners
using PROMPTS+RANDOMS mode (~ 35% mean). They were, however, lower than
those from Biograph non-TOF PET/CT scanners in NETTRUES mode (~ 60% mean)
[20]. A possible reason for the higher rate of scatter counts in the cold lung insert compared to those reported by Willowson et al. could be due to fact that the attenuation
maps from this study were vendor-provided, since attenuation maps of phantoms cannot be directly measured with MRI. Depending on the type of lung insert used in the
vendor provided maps (styrofoam or solid), this could affect the attenuation properties
and scatter estimates used in the reconstruction. However, private communication with
a representative from Siemens confirmed that the vendor-provided attenuation map
was measured from identical phantoms used in this study. Another possibility is that
the difference in geometry of the Biograph mMR scanner (i.e., longer axial FOV) may
allow for more scatter counts than the Biograph mCT or non-TOF PET/CT scanners.
Regardless, scatter counts are higher for any of these three scanners compared to 18F
when imaging 90Y. A possible explanation is that in very low count studies, the
estimated scatter distribution may be inaccurate. The scatter distribution is iteratively
estimated from the measured activity distribution and the phantom attenuation map.
When count statistics are low in an imaging dataset, residual scatter counts may
remain in regions of cold (i.e., no) activity, and the data supports this theory. For the
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low activity scan, the counts in the cold insert were approximately 76% of warm background, which is significantly higher than that measured for 18F at 26%. At the highest
90
Y activity scan, cold insert counts was approximately 33% of warm background, much
closer to that of 18F. Higher residual scatter counts in cold areas may also explain why
hot sphere RCs for low total activity scans are much lower that for 18F. Others have investigated incomplete convergence in these cold areas [32], and this remains an area of
active research.
Count recovery in the higher activity concentrated (hot) spheres was good, with mean RCs
ranging from approximately 30–75% on the highest activity imaging day (~ 2.16 MBq/ml).
These values are consistent with those from a previous ACR phantom study at two of the
institutions included in this study [23]. They are also consistent with those
reported for the same total activity level in the QUEST study for the Siemens
Biograph TOF PET/CT scanners (two iterations, 5-mm Gaussian post-reconstruction filter) and better than those for the non-TOF PET/CT scanners (all reconstructions) [20].
RCs from 90Y PET imaging were also lower than those from 18F PET imaging, with the
exception of the largest sphere size at the highest activity. We report lower 18F RCs than
Willowson et al., who reported RCs approaching near 100% for the largest sphere [20].
Discrepancy in these measurements is likely due to a difference in the method for drawing
VOIs: they used a region-growing approach, where VOIs were drawn at 50% of the maximum value, whereas we used the known sphere diameter to draw VOIs. Using an attenuation map-based method for drawing VOIs, as opposed to a region-growing approach, is
known to decrease RCs in PET images [24]. Our method is more susceptible to partial
volume effects but is more representative of what is performed for individual lesion dosimetry. As is characteristic of PET imaging studies, whether using 90Y or a standard
isotope-like 18F, RCs degraded with decreasing VOI size [21, 23, 24, 33, 34]. Combining
this with the high noise, which is characteristic of 90Y PET images, it is apparent
from Fig. 2 that very small regions of high uptake (i.e., the smallest sphere) are difficult, if not impossible, to identify. This is a limitation that must be considered in
clinical applications of 90Y PET imaging when assessing microsphere uptake in
small lesions. RCs of any given hot sphere size also slightly decreased with
decreasing activity concentration, similar to previous phantom studies [20, 23].
Contributing factors to sub-optimal recovery, especially below 18F, could include
partial volume effects, low positron statistics, and high randoms rates. Low annihilation counts, and thus low trues rates, especially combined with high randoms
rates, are limiting factors of OSEM reconstruction algorithms, as previously discussed. Low trues rates are demonstrated as a contributing factor for poorer recovery in Fig. 6f for even a standard isotope such as 18F. However, this does not account for
the entire discrepancy between these two isotopes. Handling these combined factors in iterative reconstruction algorithms is an active area of research, not just in 90Y PET imaging
[30] but also in gated-cardiac PET imaging where statistics are often low [35].
Inter-center variability, as quantified by the COV for each sphere size and activity concentration, was acceptable (< 25%) for sphere diameters ≥ 22 mm and ≥ 0.60 MBq/ml. For
the highest activity level, inter-center variability was < 23% for sphere diameters ≥ 22 mm.
In the multi-institutional phantom study by Fahey et al., nine sites tested the variability of
imaging 18F on PET/CT using an ACR phantom in preparation for a multi-institutional
clinical trial. They reported COVs in RCs of 5.9, 21.2, and 17.0% for VOI diameters 25, 16,
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and 12 mm, respectively [19]. Though these values are lower than what we measured for
our comparably sized sphere VOIs, considering the noisy nature of 90Y PET images, our
results offer promise for the ability to reliably perform multi-institutional clinical studies
of 90Y PET-based dosimetry with the Siemens Biograph mMR.
Intra-center variability was also acceptable, < 7% for sphere diameters ≥ 22 mm,
which was lower than that reported by the QUEST study for the Biograph TOF
PET/CT (5, 4, and 8% for sphere diameters 37, 28, and 22 mm, respectively) on
the highest activity imaging day (2.32 MBq/ml) [20]. Yet, for low activity concentrations, this variability increased significantly, and COVs of the spheres became
comparable to those seen at a multi-institutional level, suggesting that inter-center
variation at low activities is likely more due to scanner performance than experimental error. Conversely, the large variability seen at the inter-center level at even
the highest activity concentration (Fig. 5a–c) that is generally not present at the
intra-center level for these same activity concentration ranges (Fig. 6a–c) suggests
there could be discrepancies in the phantom preparation in addition to differences
between individual scanner performance.
Several limitations exist with this study. As mentioned previously, we used a
vendor-provided attenuation map since direct attenuation map acquisition of phantoms is not accurate on PET/MRI scanners. A study by Ziegler et al. found that
the MR-derived attenuation map of the NEMA image quality phantom, obtained
from the Siemens Biograph mMR PET/MRI scanner, only captured the photon
attenuation of water inside the phantom but failed to capture the plastic housing
of the phantom itself, which significantly degraded both the quantitative accuracy
and background variability of the PET images. Image quality was improved when a
CT-derived attenuation map of the phantom was used instead [21]. It is important
to note that this necessity for using a CT-derived attenuation map only applies to
phantom studies and is not necessary for clinical studies. Since the attenuation
maps were not measured directly from the PET/MRI scanner at the time of PET
imaging, they had to be manually registered and verified to the PET volumes in
order to incorporate into offline reconstruction. Manual registration of the attenuation map to the PET data may have introduced error during the reconstruction
procedure since it is not an exact process; however, visual inspection confirmed
satisfactory registration between the data sets. We attempted to further mitigate
any re-positioning errors both at the intra- and inter-center level by using a phantom cradle and positioning device to replicate phantom placement in the scanner
between sites. Furthermore, since we were unable to image the phantom’s plastic
housing directly with MRI, we could not see if the spheres were filled completely;
thus, the “true” activities may have actually been overestimates of what was actually filled in the spheres. Since our RCs agreed well with those reported in the
QUEST study by Willowson et al. for Siemens Biograph TOF PET/CT scanners, we
consider this effect to be negligible. Lastly, a general limitation of PET/MR imaging
is the lack of attenuation correction for coils, which may degrade quantitative
assessment of the PET images in clinical studies. Since we are assessing only the
PET camera performance in this study and not the MR-based attenuation correction algorithm, we excluded coils from this study. However, this is something to
consider in clinical cases when coils are often used.
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PET/MRI scanners from other vendors, such as GE, were not included in this study
due to a lack of other vendor sites at the time of conducting this study. Future work
will test the performance of GE PET/MRI scanners.

Conclusions
90
Y PET measurements from Siemens Biograph mMR (PET/MRI) scanners are acceptable and reproducible at the multi-institutional level. This study may provide insight
into the minimum activity concentrations (≥ 0.60 MBq/ml) and VOI size (≥ 22 mm
diameter) for accurate and reproducible measurements across institutions. Performance
is comparable to that of its TOF PET/CT counterpart and may suggest that multiinstitutional clinical studies of 90Y PET-based dosimetry using Siemens hybrid PET
scanners can include both PET/MRI and TOF PET/CT scanners, although MRI may
offer additional advantages, such as superior soft-tissue contrast for easy delineation of
liver lesions.
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